Wang Jingzhen, Xie Hongqiang, Zou Yang, Gao Ming, Wang Lijuan, Liu Xiaowei, Huang Se-Xin, Yan Junhao, Gao Yuan
State Key Laboratory of Reproductive Medicine and Offspring Health, Center for Reproductive Medicine, Cheeloo College of Medicine, Institute of Women, Children and Reproductive Health, Shandong University, 157 Jingliu Road, Jinan, 250012, Shandong, China.
National Research Center for Assisted Reproductive Technology and Reproductive Genetics, Shandong University, Jinan, 250012, Shandong, China.
BMC Pregnancy Childbirth. 2025 May 3;25(1):530. doi: 10.1186/s12884-025-07621-0.
While zygotes lacking pronuclei (0PN) or exhibiting a single pronucleus (1PN) may theoretically yield diploid embryos with developmental potential, current clinical protocols predominantly exclude these embryos from use. In the population undergoing preimplantation genetic testing for structural rearrangements (PGT-SR), there is a high rate of chromosomal aneuploidy abnormalities and needs a large number of embryos to obtain euploid embryos, so we will explore whether 0PN and 1PN embryos can be an option for them.
This retrospective analysis examined pronuclear development in 4,868 zygotes derived from 4,902 injected metaphase II (MII) oocytes across 422 assisted reproductive cycles. In a subset of 54 cycles (12.8%), preimplantation genetic testing for structural rearrangements (PGT-SR) was implemented for blastocysts originating from 0PN and 1PN embryos that progressed to Day 5/6 development stage prior to vitrification. Comprehensive genomic haplotyping was performed on 343 embryos within this subgroup, including 33 0PN-derived, 36 1PN-derived, and 274 conventional 2PN-derived specimens. The investigation's primary endpoint focused on neonatal survival outcomes, while secondary assessments evaluated both embryo transfer suitability and chromosomal normality rates.
Compared to 2PN embryos, the proportion of 0PN and 1PN embryos developing into blastocysts is significantly lower (5.41%, 21.56% vs. 56.51%, p-value < 0.001); the euploid rate of 0PN blastocysts is not statistically different from that of 2PN blastocysts (18.18% vs. 33.21%, p-value = 0.111), but significantly lower for 1PN blastocysts (11.11% vs. 33.21%, p-value = 0.004). In 54 cycles involving 0PN and 1PN blastocysts, the inclusion of 0PN and 1PN embryos resulted in an increase in the number of frozen embryos (5.81 ± 3.55 vs. 7.09 ± 3.52, p-value = 0.063), transferable embryos (1.59 ± 1.25 vs. 1.78 ± 1.30, p-value = 0.452), embryos transferred (0.98 ± 0.76 vs. 1.07 ± 0.75, p-value = 0.526), and patients undergoing transfer (74.07% vs. 79.63%, p-value = 0.494), although these changes were not statistically significant. The five 0PN and 1PN embryos transferred resulted in three live births, which was not a significant increase (56.36% vs. 56.67%, p-value = 0.974).
Chromosome abnormalities did not increase the occurrence of abnormal fertilization. There were already a large number of embryos in the PGT-SR population, and routine inclusion of 0PN and 1PN embryos in the PGT-SR cycle is not recommended in this study. Priority should be given to the transfer of 2PN embryos. If a couple receives fewer than three 2PN embryos, or no 2PN embryos at all, it may be considered to include 0PN and 1PN embryos, with preference given to the use of 0PN. Furthermore, genome-wide ploidy and haplotyping are recommended for detection, and aneuploid and ploidy abnormalities are excluded.
虽然缺乏原核(0PN)或显示单个原核(1PN)的受精卵理论上可能产生具有发育潜力的二倍体胚胎,但目前的临床方案主要将这些胚胎排除在使用范围之外。在接受结构重排植入前基因检测(PGT-SR)的人群中,染色体非整倍体异常发生率很高,需要大量胚胎才能获得整倍体胚胎,因此我们将探讨0PN和1PN胚胎是否可以成为他们的一个选择。
这项回顾性分析研究了来自422个辅助生殖周期中4902个注射中期II(MII)卵母细胞的4868个受精卵的原核发育情况。在54个周期(12.8%)的子集中,对源自0PN和1PN胚胎且在玻璃化前发育到第5/6天阶段的囊胚进行结构重排植入前基因检测(PGT-SR)。对该亚组中的343个胚胎进行了全面的基因组单倍型分析,包括33个源自0PN的、36个源自1PN的和274个传统2PN衍生的样本。该研究的主要终点集中在新生儿存活结局,而次要评估则评估胚胎移植适宜性和染色体正常率。
与2PN胚胎相比,0PN和1PN胚胎发育成囊胚的比例显著更低(5.41%,21.56%对56.51%,p值<0.001);0PN囊胚的整倍体率与2PN囊胚无统计学差异(18.18%对33.21%,p值=0.111),但1PN囊胚显著更低(11.11%对33.21%,p值=0.004)。在涉及0PN和1PN囊胚的54个周期中(涉及0PN和1PN胚胎),纳入0PN和1PN胚胎导致冷冻胚胎数量增加(5.81±3.55对7.09±3.52,p值=0.063),可移植胚胎数量增加(1.59±1.25对1.78±1.30,p值=0.452),移植胚胎数量增加(0.98±0.76对1.07±0.75,p值=0.526),以及接受移植的患者数量增加(74.07%对79.63%,p值=0.494),尽管这些变化无统计学意义。移植的5个0PN和1PN胚胎中有3个活产,这并非显著增加(56.36%对56.67%,p值=0.974)。
染色体异常并未增加异常受精的发生率。PGT-SR人群中已有大量胚胎,本研究不建议在PGT-SR周期中常规纳入0PN和1PN胚胎。应优先移植2PN胚胎。如果一对夫妇获得的2PN胚胎少于3个,或根本没有2PN胚胎,可以考虑纳入0PN和1PN胚胎,优先使用0PN。此外,建议进行全基因组倍性和单倍型分析检测,并排除非整倍体和倍性异常。